Avenir Corporation’s Cytosorbents Corp CTSO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$6.47M Buy
5,058,537
+13,619
+0.3% +$17.4K 0.67% 22
2025
Q1
$5.04M Buy
5,044,918
+1,950,972
+63% +$1.95M 0.53% 23
2024
Q4
$2.82M Buy
3,093,946
+118,387
+4% +$108K 0.29% 28
2024
Q3
$4.46M Buy
2,975,559
+5,297
+0.2% +$7.95K 0.45% 23
2024
Q2
$2.09M Sell
2,970,262
-202,434
-6% -$142K 0.2% 26
2024
Q1
$3.01M Buy
3,172,696
+121,294
+4% +$115K 0.26% 25
2023
Q4
$3.39M Buy
3,051,402
+334,005
+12% +$371K 0.29% 23
2023
Q3
$5.11M Sell
2,717,397
-2,335
-0.1% -$4.39K 0.48% 23
2023
Q2
$9.76M Buy
2,719,732
+164,179
+6% +$589K 0.86% 20
2023
Q1
$8.61M Buy
2,555,553
+108,464
+4% +$366K 0.81% 20
2022
Q4
$3.79M Buy
2,447,089
+132,235
+6% +$205K 0.38% 24
2022
Q3
$3.15M Buy
2,314,854
+149,855
+7% +$204K 0.33% 25
2022
Q2
$4.74M Sell
2,164,999
-11,510
-0.5% -$25.2K 0.45% 25
2022
Q1
$6.94M Buy
2,176,509
+389,234
+22% +$1.24M 0.55% 25
2021
Q4
$7.49M Buy
1,787,275
+391,890
+28% +$1.64M 0.58% 23
2021
Q3
$11.3M Buy
1,395,385
+28,836
+2% +$234K 0.95% 22
2021
Q2
$10.3M Buy
1,366,549
+1,007,679
+281% +$7.61M 0.82% 24
2021
Q1
$3.12M Buy
358,870
+152,130
+74% +$1.32M 0.27% 30
2020
Q4
$1.65M Buy
206,740
+16,500
+9% +$132K 0.16% 38
2020
Q3
$1.52M Buy
190,240
+22,520
+13% +$180K 0.16% 38
2020
Q2
$1.66M Buy
167,720
+17,120
+11% +$169K 0.19% 37
2020
Q1
$1.16M Hold
150,600
0.16% 41
2019
Q4
$580K Hold
150,600
0.06% 54
2019
Q3
$758K Buy
150,600
+5,300
+4% +$26.7K 0.08% 52
2019
Q2
$960K Buy
145,300
+58,060
+67% +$384K 0.1% 49
2019
Q1
$660K Buy
87,240
+10,850
+14% +$82.1K 0.07% 52
2018
Q4
$617K Buy
76,390
+34,135
+81% +$276K 0.08% 52
2018
Q3
$545K Buy
42,255
+11,185
+36% +$144K 0.06% 56
2018
Q2
$354K Buy
+31,070
New +$354K 0.04% 60